Research ArticleArticle
Open Access
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab
Philip J. Mease, Filip Van den Bosch, Joachim Sieper, Yinglin Xia, Aileen L. Pangan and In-Ho Song
The Journal of Rheumatology March 2017, jrheum.160387; DOI: https://doi.org/10.3899/jrheum.160387
Philip J. Mease
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
Filip Van den Bosch
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
Joachim Sieper
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
Yinglin Xia
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
Aileen L. Pangan
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
In-Ho Song
From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. AbbVie funded the study (), contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. P.J. Mease has received research grants and consulting fees from Amgen, Lilly, Novartis, and Pfizer. F. Van den Bosch has received consultancy and/or speaker fees from Janssen, Novartis, and UCB. P.J. Mease, MD, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; F. Van den Bosch, MD, PhD, Department of Rheumatology, Ghent University Hospital; J. Sieper, MD, PhD, Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin; Y. Xia, PhD, Department of Medicine, University of Illinois at Chicago; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; I.H. Song, MD, Immunology Clinical Development, AbbVie Inc. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 18, 2017.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab
Philip J. Mease, Filip Van den Bosch, Joachim Sieper, Yinglin Xia, Aileen L. Pangan, In-Ho Song
The Journal of Rheumatology Mar 2017, jrheum.160387; DOI: 10.3899/jrheum.160387